Press Release
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
SHENZHEN, CHINA – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.
As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.
The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).
Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.
As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.
About Vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2].
It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.
More Information About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.
The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- China Insights Consultancy’s industrial report
- Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.
- The U.S. FDA approval information can be found on the Incyte official website, as follows:
- The EMA approval information can be found on the Incyte official website, as follows:
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
U.S. sales organizations increasingly look beyond traditional training as Braintrust brings neuroscience, buyer psychology, and behavioral practice together through NeuroSelling
United States, 30th Sep 2026 — Braintrust is advancing a neuroscience-informed approach to B2B sales performance, helping enterprise organizations strengthen how sales professionals understand buyers, communicate value, and apply effective behaviors in complex selling environments. At the center of this approach is NeuroSelling, a sales methodology that combines neuroscience, buyer psychology, communication, behavioral change, practice, and reinforcement to support more consistent sales performance.
As enterprise sales environments become increasingly complex, organizations are placing greater emphasis on the human factors that influence purchasing decisions. Sales professionals must navigate multiple stakeholders, changing priorities, longer buying cycles, and increasingly informed buyers. Braintrust’s approach addresses these challenges by connecting the science of how people think and make decisions with practical sales behaviors that teams can develop and reinforce.
Through its neuroscience-backed B2B sales training, Braintrust focuses on helping sales teams understand what happens during buyer interactions and how that knowledge can translate into more effective conversations. Rather than treating sales training as a one-time event, the company’s methodology incorporates practice and reinforcement designed to help participants turn concepts into repeatable behaviors.
The approach brings together neuroscience and buyer psychology with consultative selling principles, communication techniques, and behavioral sales training. This combination is intended to help sales professionals better recognize buyer needs, engage stakeholders more effectively, and adapt their communication to different decision-making situations.
Braintrust’s work has been applied across a range of organizations and leadership teams. The company reports having worked with more than 100 organizations and 1,000 leaders, with client satisfaction exceeding 98%. Braintrust also reports that its work has influenced more than $1 billion in revenue.
These results reflect a broader focus on sales effectiveness and sales enablement: helping organizations build capabilities that extend beyond individual sales techniques. By incorporating deliberate practice and reinforcement into development programs, Braintrust aims to make behavioral change a sustained part of sales performance rather than a temporary outcome of classroom instruction.
NeuroSelling and the Science Behind Sales Behavior
NeuroSelling provides the foundation for Braintrust’s approach to understanding sales interactions through the lens of neuroscience and human behavior. The methodology examines how buyers process information, evaluate risk, build trust, and make decisions, while connecting those insights to the behaviors sales professionals use throughout the buying journey.
For enterprise sales teams, this perspective can be particularly relevant when purchasing decisions involve multiple stakeholders and significant business considerations. Sales professionals can use principles related to buyer psychology and communication to create more productive conversations and respond to the ways different buyers evaluate solutions.
The methodology also emphasizes practice. Sales professionals have opportunities to apply concepts, develop communication skills, and reinforce behaviors in realistic situations. This practice-oriented approach is designed to support sales effectiveness by moving training from theoretical knowledge toward practical application.
Building a Broader Sales Performance Ecosystem
While NeuroSelling remains central to Braintrust’s B2B sales performance approach, the company is also developing a broader ecosystem that includes NeuroCoaching and AI-enabled sales practice.
These capabilities extend the same emphasis on neuroscience, behavioral change, leadership development, and practical application into additional areas of professional development. NeuroCoaching supports the leadership and coaching dimension of sales performance, while AI-enabled practice provides another avenue for sales professionals to rehearse and strengthen their skills.
The broader ecosystem establishes a foundation for organizations seeking to connect sales training with ongoing coaching, leadership development, and technology-enabled practice. For sales leaders, this creates opportunities to reinforce behaviors after formal training and support continuous development across teams.
Braintrust’s approach is designed around the principle that improving sales performance requires more than delivering information. Effective development can involve understanding how buyers think, practicing how sales professionals communicate, reinforcing desired behaviors, and creating an environment where those behaviors can become part of everyday selling.
As U.S. companies continue to invest in sales enablement and organizational development, Braintrust is positioning NeuroSelling as the foundation of an approach that connects neuroscience with the practical realities of modern B2B selling.
For organizations evaluating SaaS sales training, software sales training, and other technology-focused sales development needs, the same principles can be applied to environments where complex products, multiple stakeholders, and evolving buyer expectations shape the sales process.
Braintrust’s work ultimately centers on a straightforward objective: helping sales organizations understand the science behind human decision-making and translate that understanding into practical behaviors that can be practiced, reinforced, and developed over time.
For more information visit https://braintrustgrowth.com/ .
About Braintrust
Braintrust provides neuroscience-informed sales training, coaching, and sales performance development for organizations seeking to improve sales effectiveness, leadership capabilities, and behavioral change. Its ecosystem includes NeuroSelling, NeuroCoaching, and AI-enabled sales practice.
Media Contact
Organization: Braintrust
Contact Person: Zach Strauss
Website: https://braintrustgrowth.com/
Email: Send Email
Country: United States
Release id: 49557
The post Braintrust Advances Neuroscience-Backed Approach to B2B Sales Performance appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
United States, 30th Sep 2026 — Way.com has introduced its Mileage Tracker App, a digital solution designed to help freelancers, self-employed professionals, independent contractors, and businesses manage work-related mileage and maintain organised travel records throughout the year. By bringing mileage logging and calculation tools together in one platform, the solution provides a convenient approach to documenting business travel and estimating related mileage expenses.
Keeping track of work-related journeys can become a time-consuming task for professionals who regularly use their vehicles for business purposes. Instead of relying on paper records or manually organising trip information, users can use a Mileage Tracker to maintain digital mileage records and keep their business travel information organised.
Way.com’s Mileage Tracking App is designed around the practical needs of professionals who need to record journeys and calculate mileage associated with work. The platform provides a centralised way to manage mileage information, making it easier to maintain a digital business mileage log and review travel records when needed.
For freelancers and self-employed professionals, consistent recordkeeping can be an important part of managing work expenses. The Mileage Tracker for freelancers and Mileage tracker for self-employed professionals provides a dedicated way to organise work-related travel information throughout the year. Independent contractors can similarly use the platform as an independent contractor mileage tracker to keep mileage records together with other business-related information.
Businesses can also use the platform to support their mileage management processes. A Business Mileage Tracker can help organisations maintain digital records of work-related journeys, while mileage calculation tools can assist with estimating travel-related expenses. This makes the platform relevant to professionals and small businesses looking for an easy mileage tracking solution.
The platform also incorporates calculation functionality to help users work with mileage-related figures. A Mileage Rate Calculator can support users when estimating mileage expenses based on applicable mileage rates, while a mileage expense calculator can provide another practical resource for reviewing business travel costs. These tools can be useful when organising information for expense management and tax-season preparation.
The Best Mileage Tracker App for any individual or business ultimately depends on its specific recordkeeping needs, but Way.com’s Mileage Tracker is positioned as a convenient digital option for professionals seeking a central place to manage work-related mileage. Its focus on mileage logging and calculation brings key mileage-management functions together rather than requiring users to maintain separate records and calculations.
For professionals who regularly travel for work, maintaining accurate information throughout the year can make mileage recordkeeping more organised. A work mileage tracker, business mileage log, or trip mileage tracker can provide a structured approach to documenting business travel, while a mileage tracker for taxes can help users keep their mileage information organised when preparing for tax season.
Way.com’s Mileage Tracker App reflects a broader shift toward digital tools for everyday business expense management. By providing mileage tracking and calculation capabilities within one platform, the solution aims to make mileage tracking made simple for freelancers, independent contractors, self-employed professionals, and businesses across the United States.
The Mileage Tracker is available through Way.com for users seeking a digital mileage recordkeeping solution for work-related travel and business mileage management.
For more information visit https://www.way.com/mileagetracker .
About Way.com
Way.com provides digital solutions designed to simplify everyday transportation and vehicle-related experiences. Its Mileage Tracker App brings mileage logging and calculation tools together to support work-related mileage tracking and business expense recordkeeping.
Media Contact:
Way.com Media Team
Email: support@way.com
Website: https://www.way.com/mileagetracker
Media Contact
Organization: Way.com
Contact Person: Support Team
Website: https://www.way.com
Email: Send Email
Country: United States
Release id: 49558
The post Way.com Introduces Mileage Tracker App to Simplify Work-Related Mileage Management appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Hong Kong S.A.R., 30th Sep 2026 – Hong Kong has always been a fast city. People here judge restaurants, products and brand videos in seconds. Attention is short and competition for it is intense, so demand for video production in Hong Kong has grown. Budgets that used to go to print ads and static banners are moving into brand films, social content and TV commercials.
But most of that video fails. It gets skipped, muted or scrolled past. Whether a video converts or disappears usually depends on decisions made before filming starts.
From “Having Video” to “Having a Video Strategy”
A few years ago, just having a video on your homepage made you stand out. Now everyone has one. Hong Kong viewers see hundreds of videos a day on the MTR, in lifts, and on YouTube, Instagram and Facebook. The brands that win attention don’t always spend more. They think differently about three things:
1. Story comes first. Viewers don’t remember drone shots. They remember how a video made them feel. The strongest brand videos in Hong Kong right now use simple, human stories: a craftsman’s hands, a customer’s change, a moment behind the scenes.
2. Get many assets from one shoot. Smart marketers plan one shoot day to produce a main brand film, a 30-second YouTube ad, vertical edits for Reels and Shorts, and stills for display ads. This can cut the cost per asset by more than half.
3. Plan distribution from day one. Without a plan to get it seen, a video is just an expensive file on a hard drive. Decide where it will live, who will see it and what they should do next in the first production meeting, not the last.
Why Local Production Still Matters
International brands entering Hong Kong often learn that content made elsewhere rarely works here. Hong Kong viewers have their own visual style and cultural rhythm: the pace of local TV ads, bilingual wordplay, local humour, and neighbourhoods that feel real.
A production house based in Hong Kong brings more than cameras. It has local talent networks, knows which locations need permits, has crews who work in Cantonese and English, and knows what appeals to both local and international viewers. That’s very hard to copy from overseas.
What Professional Production Looks Like
Brands used to working with freelancers are often surprised by a full-service studio’s process. A professional production usually has five stages:
- Discovery: learning about the brand, the audience and the business goal the video needs to meet
- Concept and strategy: writing the script, drawing storyboards and planning the shoot around where the video will run
- Production: the shoot, with professional direction, lighting and sound
- Post-production: editing, colour grading, sound design and motion graphics
- Onboarding and deployment: delivering versions sized for each platform, plus a plan to put them to work
Many studios stop before the last stage. The best ones don’t, and that’s what sets them apart.
A Studio That Sets the Standard
For a real example, look at Good Good Creative, a Hong Kong video production company based in Kwun Tong. Its clients include Cathay Pacific, Mastercard x OpenRice, Ngong Ping 360, Longchamp and the Employees Retraining Board (for public campaigns). Its work covers TV commercials, corporate video, online content and event production.
If you’re comparing studios, it helps to see how they structure their work. Every project goes through all five stages above and ends with onboarding, which focuses on getting the video in front of the right audience. It’s a good benchmark for what “full service” should mean when you judge any production partner.
The Question That Matters Most
When you brief a studio, don’t start with “we need a video.” Start with “we need viewers to do something”: book a table, trust a brand, apply for a scheme, visit a store. Good studios will push you on this, because a beautiful video with no goal is just expensive decoration.
Hong Kong viewers are watching. What matters is whether your brand’s video is worth their first three seconds, and whether it earns the next thirty.
Media Contact
Organization: trustbanana
Contact Person: Sher
Website: https://trustbanana.com
Email: Send Email
Country: Hong Kong S.A.R.
Release id: 49556
The post Video Production Hong Kong Guide 2026 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Braintrust Advances Neuroscience-Backed Approach to B2B Sales Performance
Video Production Hong Kong Guide 2026
Way.com Introduces Mileage Tracker App to Simplify Work-Related Mileage Management
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
Airwheel Wins European Product Design Award for AI Wheel Cabin 20 Inch Luxury Smart Scooter Carry on Hand Boarding Travel Electric Suitcase
-
Press Release6 days ago
Thomas Berkley of Nexus Acquisition AI Introduces Smarter Client Acquisition Strategies for Service Businesses
-
Press Release1 week ago
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
Press Release4 days ago
Piya Saliba Releases Free Community Connection Checklist to Help People Build Stronger Relationships
-
Press Release5 days ago
Whimsical Halloween Wardrobe Ready: Arshiner Kids’ Outfits Light Up the Trick-or-Treat Adventure
-
Press Release4 days ago
Painted Brick Digital Named Among Expertise.com’s Top 8 Legal Marketing Companies in Scottsdale
-
Press Release4 days ago
Gary Bassett Shares Lessons From 45 Years Across Finance and Technology
-
Press Release4 days ago
Nivia Fontanez Highlights the Often-Overlooked Role of Radiology Technologists in Patient Care